Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. DexCom, Inc.
  6. News
  7. Summary
    DXCM   US2521311074

DEXCOM, INC.

(DXCM)
  Report
Delayed Nasdaq  -  04:00 2022-06-24 pm EDT
77.67 USD   +3.27%
06/24BTIG Adjusts DexCom's Price Target to $105 From Post-Split $135, Reiterates Buy Rating
MT
06/13Come Chill at Dexcom's ‘No Pricks Parlour' With Ed Gamble for Diabetes Awareness Week, Celebrating You!
BU
06/13DEXCOM, INC. : SPLIT: 4 of 1
FA
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Citigroup Adjusts DexCom's Price Target to $525 From $630, Reiterates Buy Rating

05/17/2022 | 08:08am EDT
share with twitter
share with LinkedIn
share with facebook


© MT Newswires 2022
All news about DEXCOM, INC.
06/24BTIG Adjusts DexCom's Price Target to $105 From Post-Split $135, Reiterates Buy Rating
MT
06/13Come Chill at Dexcom's ‘No Pricks Parlour' With Ed Gamble for Diabetes Awareness ..
BU
06/13DEXCOM, INC. : SPLIT: 4 of 1
FA
06/10DEXCOM INC : Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial St..
AQ
06/08TRANSCRIPT : DexCom, Inc. Presents at William Blair’s 42nd Annual Growth Stock Confer..
CI
06/07Morgan Stanley Adjusts Price Target for DexCom to $363 From $492, Reiterates Equalweigh..
MT
06/06INSIDER SELL : Dexcom
MT
06/02Dexcom to Showcase Expanded CGM Portfolio and Industry-leading Connectivity at 82nd Sci..
BU
05/31Wall Street pulls back after last week's rally with inflation in focus
RE
05/31Unilever, DexCom rise; Gold Fields, LivePerson fall
AQ
More news
Analyst Recommendations on DEXCOM, INC.
More recommendations
Financials (USD)
Sales 2022 2 921 M - -
Net income 2022 389 M - -
Net cash 2022 486 M - -
P/E ratio 2022 79,0x
Yield 2022 -
Capitalization 30 486 M 30 486 M -
EV / Sales 2022 10,3x
EV / Sales 2023 8,24x
Nbr of Employees 6 300
Free-Float 99,5%
Chart DEXCOM, INC.
Duration : Period :
DexCom, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends DEXCOM, INC.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 16
Last Close Price 77,67 $
Average target price 120,89 $
Spread / Average Target 55,6%
EPS Revisions
Managers and Directors
Kevin Ronald Sayer Chairman, President & Chief Executive Officer
Jereme M Sylvain Chief Financial Officer & EVP-Finance
Andrew K. Balo EVP-Global Medical Affairs, Access & Evidence
Jacob S. Leach Chief Technology Officer & Executive VP
Donald M. Abbey Executive VP-IT, Quality & Regulatory Affairs
Sector and Competitors
1st jan.Capi. (M$)
DEXCOM, INC.-42.14%30 486
ABBOTT LABORATORIES-22.23%191 641
MEDTRONIC PLC-12.79%119 876
BECTON, DICKINSON AND COMPANY2.10%71 528
BAXTER INTERNATIONAL INC.-22.20%33 626
HOYA CORPORATION-30.57%31 948